Security key
22663K107
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q4 2022 13F Holders as of 31 Dec 2022
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 105,000,216
- Total 13F shares
- 54,817,398
- Share change
- -714,632
- Total reported value
- $1,003,122,430
- Put/Call ratio
- 48%
- Price per share
- $18.30
- Number of holders
- 121
- Value change
- -$14,306,281
- Number of buys
- 55
- Number of sells
- 44
Report period
Q4 2022
Institutions
121
Top holders
10
CRNX full security history
Newer quarter: Q1 2023
Previous quarter: Q3 2022
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22663K107
Recent filing periods:
Top shareholders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
5.4%
|
5,631,958
|
$110,612,000 | — | 30 Sep 2022 | |
| PERCEPTIVE ADVISORS LLC |
3/4/5
13F
|
10%+ Owner · Company |
5.1%
from 13F
|
5,321,032
|
$200,336,855 | — | 18 Apr 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.6%
|
3,752,022
|
$73,688,000 | — | 30 Sep 2022 | |
| BVF INC/IL |
13F
|
Company |
3.5%
|
3,678,947
|
$72,255,000 | — | 30 Sep 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3%
|
3,196,876
|
$62,787,000 | — | 30 Sep 2022 | |
| FMR LLC |
13F
|
Company |
2.6%
|
2,681,603
|
$52,667,000 | — | 30 Sep 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.5%
|
2,633,011
|
$51,713,000 | — | 30 Sep 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
2,356,647
|
$46,284,000 | — | 30 Sep 2022 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
2.2%
|
2,305,558
|
$45,281,000 | — | 30 Sep 2022 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
1,808,665
|
$35,522,000 | — | 30 Sep 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.3%
|
1,414,823
|
$27,787,000 | — | 30 Sep 2022 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.3%
|
1,346,652
|
$26,448,000 | — | 30 Sep 2022 | |
| EcoR1 Capital, LLC |
13F
|
Company |
1.3%
|
1,330,263
|
$26,126,000 | — | 30 Sep 2022 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.2%
|
1,310,200
|
$25,732,000 | — | 30 Sep 2022 | |
| Deep Track Capital, LP |
13F
|
Company |
1%
|
1,053,000
|
$20,681,000 | — | 30 Sep 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.84%
|
883,095
|
$17,343,000 | — | 30 Sep 2022 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.82%
|
862,286
|
$16,935,000 | — | 30 Sep 2022 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.7%
|
735,716
|
$14,449,000 | — | 30 Sep 2022 | |
| Opaleye Management Inc. |
13F
|
Company |
0.64%
|
671,300
|
$13,184,000 | — | 30 Sep 2022 | |
| Novo Holdings A/S |
13F
|
Company |
0.6%
|
631,627
|
$12,405,000 | — | 30 Sep 2022 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.6%
|
626,552
|
$12,305,000 | — | 30 Sep 2022 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.51%
|
536,070
|
$10,528,000 | — | 30 Sep 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
0.49%
|
519,256
|
$10,198,000 | — | 30 Sep 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.46%
|
478,382
|
$9,395,000 | — | 30 Sep 2022 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.43%
|
455,419
|
$8,944,000 | — | 30 Sep 2022 | |
| MPM BioImpact LLC |
13F
|
Company |
0.35%
|
364,710
|
$7,163,000 | — | 30 Sep 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.33%
|
341,482
|
$6,706,000 | — | 30 Sep 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.32%
|
336,190
|
$6,603,000 | — | 30 Sep 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.31%
|
321,752
|
$6,319,000 | — | 30 Sep 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.28%
|
296,591
|
$5,825,000 | — | 30 Sep 2022 | |
| Walleye Capital LLC |
13F
|
Company |
0.24%
|
250,014
|
$4,910,000 | — | 30 Sep 2022 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.18%
|
189,848
|
$3,732,000 | — | 30 Sep 2022 | |
| FIRST MANHATTAN CO. LLC. |
13F
|
Company |
0.14%
|
152,200
|
$2,989,000 | — | 30 Sep 2022 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.14%
|
149,027
|
$2,927,000 | — | 30 Sep 2022 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.14%
|
147,000
|
$3,124,000 | — | 30 Sep 2022 | |
| New Leaf Venture Partners, L.L.C. |
13F
|
Company |
0.13%
|
141,000
|
$2,769,000 | — | 30 Sep 2022 | |
| Monarch Partners Asset Management LLC |
13F
|
Company |
0.12%
|
130,860
|
$2,570,000 | — | 30 Sep 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.12%
|
128,500
|
$2,524,000 | — | 30 Sep 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
122,668
|
$2,409,000 | — | 30 Sep 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.1%
|
102,012
|
$2,004,000 | — | 30 Sep 2022 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.09%
|
99,068
|
$1,946,000 | — | 30 Sep 2022 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.09%
|
92,324
|
$1,813,000 | — | 30 Sep 2022 | |
| HighVista Strategies LLC |
13F
|
Company |
0.09%
|
92,047
|
$1,808,000 | — | 30 Sep 2022 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.09%
|
90,460
|
$1,777,000 | — | 30 Sep 2022 | |
| Swiss National Bank |
13F
|
Company |
0.08%
|
88,000
|
$1,728,000 | — | 30 Sep 2022 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
78,995
|
$1,551,000 | — | 30 Sep 2022 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.07%
|
75,453
|
$1,482,000 | — | 30 Sep 2022 | |
| CITIGROUP INC |
13F
|
Company |
0.07%
|
70,472
|
$1,384,000 | — | 30 Sep 2022 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.06%
|
61,635
|
$1,212,000 | — | 30 Sep 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
59,456
|
$1,168,000 | — | 30 Sep 2022 |
Institutional Holders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) as of Q4 2022
As of 31 Dec 2022,
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,817,398 shares.
The largest 10 holders included
DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, BlackRock Inc., BRAIDWELL LP, ORBIMED ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, BVF INC/IL, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, and STATE STREET CORP.
This page lists
121
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
118
Q4 2022 holders
121
Holder diff
3
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.